Literature DB >> 11392326

Long-term follow-up of a randomized trial comparing the combination of cyclophosphamide with total body irradiation or busulfan as conditioning regimen for patients receiving HLA-identical marrow grafts for acute myeloblastic leukemia in first complete remission.

D Blaise, D Maraninchi, M Michallet, J Reiffers, J P Jouet, N Milpied, A Devergie, M Attal, J J Sotto, M Kuentz, N Ifrah, C Dauriac, P Bordigoni, N Gratecos, F Guilhot, D Guyotat, E Gluckman, J P Vernant.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11392326     DOI： 10.1182/blood.v97.11.3669

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  15 in total

1.  Phase 1/2 trial of total marrow and lymph node irradiation to augment reduced-intensity transplantation for advanced hematologic malignancies.

Authors:  Joseph Rosenthal; Jeffrey Wong; Anthony Stein; Dajun Qian; Debbie Hitt; Hossameldin Naeem; Andrew Dagis; Sandra H Thomas; Stephen Forman
Journal:  Blood       Date:  2010-09-28       Impact factor: 22.113

2.  Reduced-toxicity conditioning prior to allogeneic stem cell transplantation improves outcome in patients with myeloid malignancies.

Authors:  Claire Oudin; Patrice Chevallier; Sabine Furst; Thierry Guillaume; Jean El Cheikh; Jacques Delaunay; Luca Castagna; Catherine Faucher; Angela Granata; Raynier Devillier; Christian Chabannon; Benjamin Esterni; Norbert Vey; Mohamad Mohty; Didier Blaise
Journal:  Haematologica       Date:  2014-08-01       Impact factor: 9.941

3.  Image-guided total-marrow irradiation using helical tomotherapy in patients with multiple myeloma and acute leukemia undergoing hematopoietic cell transplantation.

Authors:  Jeffrey Y C Wong; Joseph Rosenthal; An Liu; Timothy Schultheiss; Stephen Forman; George Somlo
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-09-09       Impact factor: 7.038

4.  Myeloablative conditioning with total body irradiation for AML: Balancing survival and pulmonary toxicity.

Authors:  Sarah J Stephens; Samantha Thomas; David A Rizzieri; Mitchell E Horwitz; Nelson J Chao; Ashley M Engemann; Martha Lassiter; Chris R Kelsey
Journal:  Adv Radiat Oncol       Date:  2016-07-15

5.  Comparison of target volume and clinical effects of four radiotherapy plans for acute lymphoblastic leukemia prior to hematopoietic stem cell transplantation.

Authors:  Yalei Lin; Fanyang Kong; Hongfei Li; Dandan Xu; Fei Jia; Xudong Zhang; Baohong Wang; Guowen Li
Journal:  Mol Med Rep       Date:  2018-06-27       Impact factor: 2.952

6.  Energy-dependent OAR sparing and dose conformity for total marrow irradiation of obese patients.

Authors:  Amanda J Cherpak; Thalat Monajemi; Krista Chytyk-Praznik; Liam Mulroy
Journal:  J Appl Clin Med Phys       Date:  2018-08-11       Impact factor: 2.102

7.  TBI with lung dose reduction does not improve hematopoietic cell homing to BM during allogeneic transplantation.

Authors:  A K Singh; J Chen; R Calado; A Sowers; J B Mitchell; A J Barrett
Journal:  Bone Marrow Transplant       Date:  2009-06-15       Impact factor: 5.483

8.  Suberoylanilide hydroxamic acid induces hypersensitivity to radiation therapy in acute myelogenous leukemia cells expressing constitutively active FLT3 mutants.

Authors:  Xufeng Chen; Eric H Radany; Patty Wong; Shenglin Ma; Kan Wu; Bing Wang; Jeffrey Y C Wong
Journal:  PLoS One       Date:  2013-12-19       Impact factor: 3.240

9.  [Containing total marrow irradiation conditioning regimen for patients with leukemia undergoing hematopoietic stem cell transplantation].

Authors:  X Y Zhao; H F Wang
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2020-06-14

10.  Evaluation and improvement the safety of total marrow irradiation with helical tomotherapy using repeat failure mode and effects analysis.

Authors:  Jiuling Shen; Xiaoyong Wang; Di Deng; Jian Gong; Kang Tan; Hongli Zhao; Zhirong Bao; Jinping Xiao; An Liu; Yunfeng Zhou; Hui Liu; Conghua Xie
Journal:  Radiat Oncol       Date:  2019-12-27       Impact factor: 3.481
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.